Orthogon pan-coronavirus inhibitor

Orthogon Therapeutics is developing an oral small-molecule pan-coronavirus inhibitor that acts on virus-specific host targets to inhibit coronavirus replication. The company is using its proprietary biophysics- and structure-based drug discovery platform to develop this preclinical-stage antiviral therapeutic. While Orthogon's lead program focuses on BK and JC polyomavirus infections in transplant patients, the company has a pan-coronavirus inhibitor program in its pipeline that is in the discovery/preclinical stage. The specific compound name, exact molecular targets, and detailed mechanism of action have not been publicly disclosed. Orthogon Therapeutics is a privately held R&D company headquartered in Canton, Massachusetts, with a branch in Leuven, Belgium, and is part of the Pledge Therapeutics family of companies.

Other names

Orthogon pan-coronavirus programOrthogon Therapeutics-virus-specific host targets-small molecule-oral-Coronavirus infections